Pharmacogenomics and public health: implementing 'populationalized' medicine.

Pharmacogenomics are frequently considered in personalized medicine to maximize therapeutic benefits and minimize adverse drug reactions. However, there is a movement towards applying this technology to populations, which may produce the same benefits, while saving already scarce health resources. We conducted a narrative literature review to examine how pharmacogenomics and public health can constructively intersect, particularly in resource-poor settings. We identified 27 articles addressing the research question. Real and theoretical connections between public health and pharmacogenomics were presented in the areas of disease, drugs and public policy. Suggested points for consideration, such as educational efforts and cultural acceptability, were also provided. Including pharmacogenomics in public health can result in both health-related and economic benefits. Including pharmacogenomics in public health holds promise but deserves extensive consideration. To fully realize the benefits of this technology, support is needed from private, public and governmental sectors in order to ensure the appropriateness within a society.

[1]  Patricia C. Kuszler,et al.  A Review of Public Policy Issues in Promoting the Development and Commercialization of Pharmacogenomic Applications: Challenges and Implications , 2008, Drug metabolism reviews.

[2]  S. Brahmachari,et al.  From diversity to delivery: the case of the Indian Genome Variation initiative , 2008, Nature Reviews Genetics.

[3]  G. Patrinos,et al.  Relevance of pharmacogenomics for developing countries in Europe , 2011, Drug metabolism and drug interactions.

[4]  Harnessing genomics to improve health in the Eastern Mediterranean Region – an executive course in genomics policy , 2005, Health research policy and systems.

[5]  M. Ameen.  Cutaneous leishmaniasis: disease susceptibility and pharmacogenetic implications. , 2009, Pharmacogenomics.

[6]  B. Williams-Jones,et al.  Pharmacogenomic technologies: a necessary "luxury" for better global public health? , 2011, Globalization and health.

[7]  M. Msellem,et al.  CYP2C8 polymorphism frequencies among malaria patients in Zanzibar , 2005, European Journal of Clinical Pharmacology.

[8]  Vassiliki Gkantouna,et al.  Population-specific documentation of pharmacogenomic markers and their allelic frequencies in FINDbase. , 2011, Pharmacogenomics.

[9]  Samiul Hasan,et al.  Prioritizing Genomic Drug Targets in Pathogens: Application to Mycobacterium tuberculosis , 2006, PLoS Comput. Biol..

[10]  G. Patrinos,et al.  Golden Helix Pharmacogenomics Days: educational activities on pharmacogenomics and personalized medicine. , 2012, Pharmacogenomics.

[11]  U. Fuhr,et al.  Chapter 13 - Applications of genotyping and phenotyping for clinically-relevant polymorphisms of drug metabolizing enzymes and drug transporters , 2004 .

[12]  Andy Haines,et al.  A framework for mandatory impact evaluation to ensure well informed public policy decisions , 2010, The Lancet.

[13]  R. Davis,et al.  A public health approach to pharmacogenomics and gene-based diagnostic tests. , 2006, Pharmacogenomics.

[14]  Kathryn A Phillips,et al.  An introduction to cost-effectiveness and cost-benefit analysis of pharmacogenomics. , 2003, Pharmacogenomics.

[15]  A. Daar,et al.  South Africa: from species cradle to genomic applications , 2008, Nature Reviews Genetics.

[16]  S. Lee.  Racializing drug design: implications of pharmacogenomics for health disparities. , 2005, American journal of public health.

[17]  Abdallah S. Daar,et al.  Genomics, public health and developing countries: the case of the Mexican National Institute of Genomic Medicine (INMEGEN) , 2008, Nature Reviews Genetics.

[18]  Abdallah S. Daar,et al.  Pharmacogenetics and geographical ancestry: implications for drug development and global health , 2005, Nature Reviews Genetics.

[19]  Felix W Frueh,et al.  Pharmacogenomics steps toward personalized medicine. , 2005, Personalized medicine.

[20]  Peter A Singer,et al.  How can developing countries harness biotechnology to improve health? , 2007, BMC public health.

[21]  Abdallah S. Daar,et al.  Genomic medicine and developing countries: creating a room of their own , 2008, Nature Reviews Genetics.

[22]  A. Smart,et al.  The promise of pharmacogenetics: assessing the prospects for disease and patient stratification. , 2006, Studies in history and philosophy of biological and biomedical sciences.

[23]  K. Neville,et al.  Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications. , 2006, The oncologist.

[24]  B. Roy,et al.  Pharmacogenomics of anti-TB drugs-related hepatotoxicity. , 2008, Pharmacogenomics.

[25]  A. Daar,et al.  Harnessing Genomics and Biotechnology to Improve Global Health Equity , 2001, Science.

[26]  G. Drusano,et al.  Isoniazid Bactericidal Activity and Resistance Emergence: Integrating Pharmacodynamics and Pharmacogenomics To Predict Efficacy in Different Ethnic Populations , 2007, Antimicrobial Agents and Chemotherapy.

[27]  George P Patrinos,et al.  Realities and expectations of pharmacogenomics and personalized medicine: impact of translating genetic knowledge into clinical practice. , 2010, Pharmacogenomics.

[28]  T. Pang.  The impact of genomics on global health. , 2002, American journal of public health.

[29]  Critical appraisal of the private genetic and pharmacogenomic testing environment in Greece. , 2011, Personalized medicine.

[30]  P. Fortina,et al.  Institutional Profile: Golden Helix Institute of Biomedical Research: interdisciplinary research and educational activities in pharmacogenomics and personalized medicine. , 2012, Pharmacogenomics.

[31]  General considerations for integrating pharmacogenomics into mainstream medical practice , 2010, Human Genomics.

[32]  D. Cooper,et al.  A critical view of the general public's awareness and physicians' opinion of the trends and potential pitfalls of genetic testing in Greece. , 2011, Personalized medicine.

[33]  E. Gil Berglund,et al.  CYP2C8 and antimalaria drug efficacy , 2007, Pharmacogenomics.

[34]  A. Dodoo,et al.  Pharmacogenetics in Ghana: reviewing the evidence. , 2011, Ghana medical journal.

[35]  H. Burton,et al.  Developing Stakeholder Involvement for Introducing Public Health Genomics into Public Policy , 2008, Public Health Genomics.

[36]  C. V. D. van de Velde,et al.  Clinical Implications of CYP2D6 Genotyping in Tamoxifen Treatment for Breast Cancer , 2009, Clinical Cancer Research.

[37]  "Harnessing genomics to improve health in Africa" – an executive course to support genomics policy , 2004, Health research policy and systems.

[38]  M. Kirkman.  Public health and the challenge of genomics , 2005, Australian and New Zealand journal of public health.

[39]  A. Daar,et al.  Universal health care, genomic medicine and Thailand: investing in today and tomorrow , 2008, Nature Reviews Genetics.